Therapeutic effects of an oral gonadotropin‐releasing hormone receptor antagonist, relugolix, on preventing premature ovulation in mild ovarian stimulation for IVF
| Autor: | Kazuki Nakao, Keiji Kuroda, Takashi Horikawa, Azusa Moriyama, Hiroyasu Juen, Akiko Itakura, Hideaki Watanabe, Satoru Takamizawa, Yuko Ojiro, Koji Nakagawa, Rikikazu Sugiyama |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Reproductive Medicine and Biology, Vol 21, Iss 1, Pp n/a-n/a (2022) |
| Druh dokumentu: | article |
| ISSN: | 1447-0578 1445-5781 |
| DOI: | 10.1002/rmb2.12422 |
| Popis: | Abstract Purpose Can relugolix, a novel oral gonadotropin‐releasing hormone receptor (GnRH) antagonist, function as an alternative ovulation inhibitor to GnRH antagonist injections? Methods This single‐center, cross‐sectional retrospective study compared premature ovulation rates and clinical outcomes in IVF treatment after mild ovarian stimulation with 40 mg of relugolix (relugolix group) or 0.25‐mg injections of ganirelix acetate or cetrorelix acetate (injection group) between March 2019 and January 2020. Of 247 infertile women (256 IVF cycles) aged ≤42 years, 223 women (230 cycles) were evaluated. In the relugolix and injection groups, we compared 104 and 85 cycles after GnRH antagonist use before the LH surge (LH levels |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|